Venrock Healthcare Capital Partners Ii, L.p. - Net Worth and Insider Trading

Venrock Healthcare Capital Partners Ii, L.p. Net Worth

The estimated net worth of Venrock Healthcare Capital Partners Ii, L.p. is at least $17 Million dollars as of 2024-11-29. Venrock Healthcare Capital Partners Ii, L.p. is the 10% Owner of KalVista Pharmaceuticals Inc and owns about 1,544,112 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $16 Million. Venrock Healthcare Capital Partners Ii, L.p. is the 10% Owner of Vistagen Therapeutics Inc and owns about 687,909 shares of Vistagen Therapeutics Inc (VTGN) stock worth over $2 Million. Venrock Healthcare Capital Partners Ii, L.p. is also the 10% Owner of Tricida Inc and owns about 3,751,406 shares of Tricida Inc (TCDAQ) stock worth over $38. Details can be seen in Venrock Healthcare Capital Partners Ii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Venrock Healthcare Capital Partners Ii, L.p. has not made any transactions after 2022-10-26 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Venrock Healthcare Capital Partners Ii, L.p.

Venrock Healthcare Capital Partners Ii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Venrock Healthcare Capital Partners Ii, L.p. owns 10 companies in total, including Cogent Biosciences Inc (COGT) , Altimmune Inc (ALT) , and Constellation Pharmaceuticals Inc (CNST) among others .

Click here to see the complete history of Venrock Healthcare Capital Partners Ii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Venrock Healthcare Capital Partners Ii, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
COGT	Cogent Biosciences Inc	2020-08-13	10 percent owner
ALT	Altimmune Inc	2021-02-25	10 percent owner
CNST	Constellation Pharmaceuticals Inc	2019-12-13	10 percent owner
		2018-08-13	10 percent owner
		2019-03-18	10 percent owner
		2019-03-06	10 percent owner
		2015-06-16	10 percent owner
		2014-08-05	10 percent owner
		2022-10-26	10 percent owner
		2022-07-12	10 percent owner

Venrock Healthcare Capital Partners Ii, L.p. Latest Holdings Summary

Venrock Healthcare Capital Partners Ii, L.p. currently owns a total of 3 stocks. Among these stocks, Venrock Healthcare Capital Partners Ii, L.p. owns 1,544,112 shares of KalVista Pharmaceuticals Inc (KALV) as of March 18, 2019, with a value of $16 Million and a weighting of 89.38%. Venrock Healthcare Capital Partners Ii, L.p. owns 687,909 shares of Vistagen Therapeutics Inc (VTGN) as of July 12, 2022, with a value of $2 Million and a weighting of 10.62%. Venrock Healthcare Capital Partners Ii, L.p. also owns 3,751,406 shares of Tricida Inc (TCDAQ) as of October 26, 2022, with a value of $38 and a weighting of 0%.

Latest Holdings of Venrock Healthcare Capital Partners Ii, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KALV	KalVista Pharmaceuticals Inc	2019-03-18	1,544,112	10.09	15,580,090
VTGN	Vistagen Therapeutics Inc	2022-07-12	687,909	2.69	1,850,475
TCDAQ	Tricida Inc	2022-10-26	3,751,406	0.00	38

Holding Weightings of Venrock Healthcare Capital Partners Ii, L.p.

Venrock Healthcare Capital Partners Ii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Ii, L.p. has made a total of 0 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years. The most-recent trade in KalVista Pharmaceuticals Inc is the sale of 500,000 shares on March 18, 2019, which brought Venrock Healthcare Capital Partners Ii, L.p. around $14 Million.

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Ii, L.p. has made a total of 1 transactions in Vistagen Therapeutics Inc (VTGN) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Vistagen Therapeutics Inc is the sale of 2,000 shares on July 12, 2022, which brought Venrock Healthcare Capital Partners Ii, L.p. around $53,400.

According to the SEC Form 4 filings, Venrock Healthcare Capital Partners Ii, L.p. has made a total of 20 transactions in Tricida Inc (TCDAQ) over the past 5 years, including 19 buys and 1 sells. The most-recent trade in Tricida Inc is the sale of 6,451,540 shares on October 26, 2022, which brought Venrock Healthcare Capital Partners Ii, L.p. around $3 Million.

Insider Trading History of Venrock Healthcare Capital Partners Ii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Venrock Healthcare Capital Partners Ii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Venrock Healthcare Capital Partners Ii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Venrock Healthcare Capital Partners Ii, L.p. is -44.82%. GuruFocus also compares Venrock Healthcare Capital Partners Ii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Venrock Healthcare Capital Partners Ii, L.p. within 3 months outperforms 8 times out of 19 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Venrock Healthcare Capital Partners Ii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Venrock Healthcare Capital Partners Ii, L.p.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-20.72
Relative Return to S&P 500(%)	-23.44

Venrock Healthcare Capital Partners Ii, L.p. Ownership Network

Ownership Network List of Venrock Healthcare Capital Partners Ii, L.p.

No Data

Ownership Network Relation of Venrock Healthcare Capital Partners Ii, L.p.

Venrock Healthcare Capital Partners Ii, L.p. Owned Company Details

What does Cogent Biosciences Inc do?

Who are the key executives at Cogent Biosciences Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Cogent Biosciences Inc. Other key executives at Cogent Biosciences Inc include 10 percent owner & other: See Remarks Fairmount Funds Management Llc , Chief Legal Officer Evan Kearns , and Chief Financial Officer John L. Green .

Cogent Biosciences Inc (COGT) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in Cogent Biosciences Inc (COGT). Other recent insider transactions involving Cogent Biosciences Inc (COGT) include a net purchase of 800,000 shares made by Fairmount Funds Management Llc ,

In summary, during the past 3 months, insiders sold 0 shares of Cogent Biosciences Inc (COGT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cogent Biosciences Inc (COGT) were sold and 800,000 shares were bought by its insiders, resulting in a net purchase of 800,000 shares.

Cogent Biosciences Inc (COGT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cogent Biosciences Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 0 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does Constellation Pharmaceuticals Inc do?

Who are the key executives at Constellation Pharmaceuticals Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Constellation Pharmaceuticals Inc. Other key executives at Constellation Pharmaceuticals Inc include Chief Financial Officer Emma Reeve , 10 percent owner Column Group L P , and See Remarks Karen Valentine .

Constellation Pharmaceuticals Inc (CNST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Constellation Pharmaceuticals Inc (CNST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Constellation Pharmaceuticals Inc (CNST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Constellation Pharmaceuticals Inc (CNST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Constellation Pharmaceuticals Inc Insider Transactions

No Available Data

What does Bellerophon Therapeutics Inc do?

Who are the key executives at Bellerophon Therapeutics Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Bellerophon Therapeutics Inc. Other key executives at Bellerophon Therapeutics Inc include 10 percent owner Puissance Life Science Opportunities Fund Vi , VP of Business Operations Parag Suresh Shah , and See Remarks Martin Dekker .

Bellerophon Therapeutics Inc (BLPH) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in Bellerophon Therapeutics Inc (BLPH). Other recent insider transactions involving Bellerophon Therapeutics Inc (BLPH) include a net sale of 1,076,841 shares made by Puissance Life Science Opportunities Fund Vi , and a net sale of 134,421 shares made by Puissance Capital Fund (gp) Llc .

In summary, during the past 3 months, insiders sold 0 shares of Bellerophon Therapeutics Inc (BLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,211,262 shares of Bellerophon Therapeutics Inc (BLPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,211,262 shares.

Bellerophon Therapeutics Inc (BLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Bellerophon Therapeutics Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Medical Officer Paul K. Audhya , Chief Development Officer Christopher Yea , and CFO and Secretary Benjamin L Palleiko .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 155,123 shares made by Benjamin L Palleiko , and a net sale of 95,977 shares made by Christopher Yea .

In summary, during the past 3 months, insiders sold 41,171 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 41,171 shares. During the past 18 months, 600,355 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 650,662 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

What does Shockwave Medical Inc do?

Who are the key executives at Shockwave Medical Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Shockwave Medical Inc. Other key executives at Shockwave Medical Inc include Chief Commercial Officer Isaac Zacharias , VP & Finance Trinh Phung , and director & President & CEO Douglas Evan Godshall .

Shockwave Medical Inc (SWAV) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in Shockwave Medical Inc (SWAV). Other recent insider transactions involving Shockwave Medical Inc (SWAV) include a net sale of 40,000 shares made by Isaac Zacharias , a net sale of 24,000 shares made by Frank T Watkins , and a net sale of 70,000 shares made by Douglas Evan Godshall .

In summary, during the past 3 months, insiders sold 0 shares of Shockwave Medical Inc (SWAV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 206,104 shares of Shockwave Medical Inc (SWAV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 206,104 shares.

Shockwave Medical Inc (SWAV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Shockwave Medical Inc Insider Transactions

No Available Data

What does ARCA biopharma Inc do?

Who are the key executives at ARCA biopharma Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of ARCA biopharma Inc. Other key executives at ARCA biopharma Inc include 10 percent owner & other: See Footnote 1 Funicular Funds, Lp , other: See Footnote 1 Funicular Fund, Lp , and other: See Remarks Jacob Ma-weaver .

ARCA biopharma Inc (ABIO) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in ARCA biopharma Inc (ABIO). Other recent insider transactions involving ARCA biopharma Inc (ABIO) include a net purchase of 634,678 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of ARCA biopharma Inc (ABIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARCA biopharma Inc (ABIO) were sold and 52,890 shares were bought by its insiders, resulting in a net purchase of 52,890 shares.

ARCA biopharma Inc (ABIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARCA biopharma Inc Insider Transactions

No Available Data

What does Adverum Biotechnologies Inc do?

Who are the key executives at Adverum Biotechnologies Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Adverum Biotechnologies Inc. Other key executives at Adverum Biotechnologies Inc include Chief Development Officer Setareh Seyedkazemi , Chief Financial Officer Linda M Rubinstein , and Chief Scientific Officer Brigit Riley .

Adverum Biotechnologies Inc (ADVM) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in Adverum Biotechnologies Inc (ADVM). Other recent insider transactions involving Adverum Biotechnologies Inc (ADVM) include a net purchase of 302,064 shares made by Braden Michael Leonard , a net purchase of 130,000 shares made by Lupher, Jr. Mark L. , and a net purchase of 100,000 shares made by Linda M Rubinstein .

In summary, during the past 3 months, insiders sold 0 shares of Adverum Biotechnologies Inc (ADVM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 620 shares of Adverum Biotechnologies Inc (ADVM) were sold and 335,064 shares were bought by its insiders, resulting in a net purchase of 334,444 shares.

Adverum Biotechnologies Inc (ADVM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adverum Biotechnologies Inc Insider Transactions

No Available Data

What does Tricida Inc do?

Who are the key executives at Tricida Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Tricida Inc. Other key executives at Tricida Inc include director & 10 percent owner Orbimed Advisors Llc , director & 10 percent owner David P Bonita , and 10 percent owner & other: *possible member of 10% group Sibling Capital Fund Ii-b L.p. .

Tricida Inc (TCDAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tricida Inc (TCDAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tricida Inc (TCDAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tricida Inc (TCDAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tricida Inc Insider Transactions

No Available Data

What does Vistagen Therapeutics Inc do?

Who are the key executives at Vistagen Therapeutics Inc?

Venrock Healthcare Capital Partners Ii, L.p. is the 10 percent owner of Vistagen Therapeutics Inc. Other key executives at Vistagen Therapeutics Inc include Chief Operating Officer Joshua S. Prince , CHIEF FINANCIAL OFFICER Cynthia Lynn Anderson , and 10 percent owner Commodore Capital Lp .

Vistagen Therapeutics Inc (VTGN) Insider Trades Summary

Over the past 18 months, Venrock Healthcare Capital Partners Ii, L.p. made no insider transaction in Vistagen Therapeutics Inc (VTGN). Other recent insider transactions involving Vistagen Therapeutics Inc (VTGN) include a net purchase of 775,756 shares made by Commodore Capital Lp ,

In summary, during the past 3 months, insiders sold 0 shares of Vistagen Therapeutics Inc (VTGN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vistagen Therapeutics Inc (VTGN) were sold and 775,756 shares were bought by its insiders, resulting in a net purchase of 775,756 shares.

Vistagen Therapeutics Inc (VTGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vistagen Therapeutics Inc Insider Transactions

No Available Data

Venrock Healthcare Capital Partners Ii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Venrock Healthcare Capital Partners Ii, L.p.. You might contact Venrock Healthcare Capital Partners Ii, L.p. via mailing address: 7 Bryant Park, 23rd Floor, New York Ny 10018.

Discussions on Venrock Healthcare Capital Partners Ii, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.